Editorial

← vista completa

Published on May 1, 2012 | http://doi.org/10.5867/medwave.2012.04.5344

Helicobacter pylori: a persistent enemy in Latin America

Helicobacter pylori: un enemigo persistente en Latinoamérica

Eduardo Freddy Orrego Escobar

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Eduardo Freddy Orrego Escobar

Director Departamento de Ciencias Básicas, Universidad Santo Tomás, Copiapó, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Orrego Escobar EF. Helicobacter pylori: a persistent enemy in Latin America. Medwave 2012;12(04):e5344 doi: 10.5867/medwave.2012.04.5344

Submission date 22/02/2012

Acceptance date 11/03/2012

Publication date 01/05/2012

Index

Article metrics

Article has no metrics.

Notes

Origin and peer review

sin revisión por pares

References

  1. Ramis IB, Fonseca TL, de Moraes EP, Fernandes MS, Mendoza-Sassi R, Rodrigues O, et al. Molecular Basis of Pathogenicity in Helicobacter pylori Clinical Isolates. J Clin Microbiol. 2010 Oct;48(10):3776-8. | CrossRef | PubMed
  2. Heise K, Bertran E, Andia M, Ferreccio C. Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol. 2009 Apr 21;15(15):1854-62. | CrossRef | PubMed
  3. Ramírez A, Sánchez R. Helicobacter pylori y Cáncer Gástrico. Rev Gastroenterol Peru. 2008 Jul-Sep;28(3):258-66. | PubMed
  4. Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylorirelated disease in Latin American and African populations. Clin Microbiol Infect. 2009 Sep;15(9):835-42. Epub 2009 Apr 10. | PubMed
  5. Correa P, Piazuelo B. Natural history of Helicobacter pylori infection. Dig Liver Dis. 2008 Jul;40(7):490-6. Epub 2008 Apr 18. | PubMed
  6. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):629-41. Epub 2010 Oct 12. | PubMed
  7. Chen VW, Abu-Elyazeed RR, Zavala DE, Ktsanes VK, Haenszel W, Cuello C, et al. Risk factors of gastric precancerous lesions in a high-risk Colombian population. I. Nutr Cancer. 1990;13(1-2):59-65. | CrossRef | PubMed
  8. Camargo M, Yepez M, Ceron C, Guerrero N, Bravo L, Correa P, et al. Age at acquisition of Helicobacter pylori infection: comparison of two areas with contrasting risk of gastric cancer. Helicobacter. 2004 Jun;9(3):262-70. | CrossRef | PubMed
  9. Harris D P, Serrano H C, Venegas E A. Vacuna en desarrollo: Helicobacter pylori. Rev Chilena Infectol. 2006 Sep;23(3):249-56. | PubMed
  10. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011 Mar;14(1):72-80. | CrossRef | PubMed